Cognition Therapeutics, Inc.

NASDAQ:CGTX

0.47 (USD) • At close November 1, 2024
Bedrijfsnaam Cognition Therapeutics, Inc.
Symbool CGTX
Munteenheid USD
Prijs 0.471
Beurswaarde 18,898,611
Dividendpercentage 0%
52-weken bereik 0.34 - 2.95
Industrie Biotechnology
Sector Healthcare
CEO Ms. Lisa Ricciardi
Website https://www.cogrx.com

An error occurred while fetching data.

Over Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment

Vergelijkbare Aandelen

ReWalk Robotics Ltd. logo

ReWalk Robotics Ltd.

RWLK

1.05 USD

Solid Biosciences Inc. logo

Solid Biosciences Inc.

SLDB

5.75 USD

MediWound Ltd. logo

MediWound Ltd.

MDWD

18.37 USD

Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp.

MDNA

0.157 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)